Want to see SE:GABA full AI Analyst Report?

Gabather AB (GABA) Price & Analysis

0 Followers

GABA Stock Chart & Stats

kr0.04

>-kr0.01(-12.89%)

At close: Mar 06 4:00 PM EST

kr0.04

>-kr0.01(-12.89%)

Day’s Range― - ―

52-Week Rangekr0.02 - kr0.13

Previous CloseN/A

Volume42.79K

Average Volume (3M)488.51K

Market Cap

kr17.40M

Enterprise Valuekr2.80M

Total Cash (Recent Filing)kr6.04M

Total Debt (Recent Filing)kr0.00

Price to Earnings (P/E)―

Beta0.86

Next Earnings

Aug 27, 2026

EPS Estimate

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.02

Shares Outstanding491,634,160

10 Day Avg. Volume541,248

30 Day Avg. Volume488,507

Financial Highlights & Ratios

PEG Ratio0.01

Price to Book (P/B)-6.10

Price to Sales (P/S)0.00

P/FCF Ratio-0.73

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Zero DebtA zero-debt balance sheet reduces interest burden and financial leverage, providing durable financing flexibility. Over a 2–6 month horizon this lowers default risk and gives management room to structure R&D funding through partnerships or equity without fixed debt repayments.

Narrowing LossesA multi-year trend of narrowing net losses signals improving cost control or program efficiency. This persistent reduction in cash burn requirements can lengthen runway between financings and makes future partnering or out-licensing negotiations less urgent and more strategic.

Focused CNS/GABAA ExpertiseA clear, focused scientific niche (GABAA modulation for CNS disorders) represents a durable competitive advantage in biotech: concentrated IP, targeted R&D, and clearer partner fit. This specialization improves odds of attractive licensing deals and efficient trial design over time.

Bears Say

Pre-revenue OperationsRemaining pre-commercial with no product revenue means the business depends on milestone/licensing events or external financing. This structural reliance increases dilution risk and makes operating continuity contingent on successful clinical readouts or partner deals within coming funding cycles.

Negative Equity & Volatile AssetsNegative shareholders' equity and meaningful asset swings reflect accumulated losses and weaken balance-sheet resilience. This structural weakness can constrain borrowing capacity, reduce negotiating leverage with partners, and increase the probability of dilutive capital raises to fund development.

Consistent Cash BurnPersistently negative operating and free cash flow with year-to-year swings creates ongoing funding pressure. Until revenue or significant licensing payments materialize, the firm will likely need external financing, raising execution and dilution risk that can materially affect long-term strategy.

GABA FAQ

What was Gabather AB’s price range in the past 12 months?

Gabather AB lowest stock price was kr0.02 and its highest was kr0.13 in the past 12 months.

What is Gabather AB’s market cap?

Gabather AB’s market cap is kr17.40M.

When is Gabather AB’s upcoming earnings report date?

Gabather AB’s upcoming earnings report date is Aug 27, 2026 which is in 47 days.

How were Gabather AB’s earnings last quarter?

Gabather AB released its earnings results on May 28, 2026. The company reported kr0 earnings per share for the quarter, the consensus estimate of kr0 by kr0.

Is Gabather AB overvalued?

According to Wall Street analysts Gabather AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Gabather AB pay dividends?

Gabather AB does not currently pay dividends.

What is Gabather AB’s EPS estimate?

Gabather AB’s EPS estimate is 0.

How many shares outstanding does Gabather AB have?

Gabather AB has 491,634,160 shares outstanding.

What happened to Gabather AB’s price movement after its last earnings report?

Gabather AB reported an EPS of kr0 in its last earnings report, expectations of kr0. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Gabather AB?

Currently, no hedge funds are holding shares in SE:GABA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Gabather AB

Gabather AB (publ) is dedicated to creating innovative pharmaceutical solutions for a range of central nervous system disorders. The company's focus includes developing medications for conditions such as psychotic illnesses, mood and anxiety disorders, pain relief, and cognitive function enhancement, notably those related to Alzheimer's disease. Founded in 2014, its operations are headquartered in Södertälje, Sweden.